Letters in Drug Design & Discovery

G. Perry
University of Texas
San Antonio, TX
USA
Email: lddd@benthamscience.org

Back

Novel Clarithromycin Analogs with C-4” 2-arylbenzimidazolyl Bishydrazide Side Chain: Synthesis and Antibacterial Evaluation

Author(s): Yunkun Qi, Ruixin Ma, Xin Li, Yue Hu, Siti Ma, Chao Cong, Xiaodong Ma, Wenping Cui, Shutao Ma.

Abstract:

A series of novel 4” -O-2-arylbenzimidazolyl derivatives of clarithromycin were synthesized and evaluated. These 4” -O-2-arylbenzimidazolyl derivatives demonstrated excellent activity against erythromycin-susceptible strains and showed remarkably improved activity against erythromycin-resistant strains compared with the references. In particular, compound 7c, which possesses the terminal 2-(2-methoxyphenyl)benzimidazolyl group on the C-4” bishydrazide side chain, not only presented the most potent activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923, exhibiting 4-fold and 4-fold higher efficacy than the parent clarithromycin, but also displayed the highest activity against erythromycin-resistant Streptococcus pneumoniae expressing the mef gene and the erm gene, which was 133-fold and 32-fold better than clarithromycin or azithromycin, respectively.

Keywords: Antibacterial activity, Benzimidazolyl derivatives, Carbamates, Clarithromycin, Resistance, Synthesis, erythromycin-susceptible strains, Streptococcus pneumoniae, Staphylococcus aureus, C-4 bishydrazide side chain, mef gene, erm gene, azithromycin, methyltransferase, macrolides, telithromycin

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 8
ISSUE: 10
Year: 2011
Page: [966 - 971]
Pages: 6
DOI: 10.2174/157018011797655269
Price: $58